A federal jury has found that Teva must pay GlaxoSmithKline $235 million in a carve-out patent case over heart drug Coreg.

Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as companies increasingly focus on rare disease meds.

Russia is pushing back on an issue that has raised concerns around the world: cancer drug prices.

Biopharma and its investors are breathing a sigh of relief on reports of the White House's drug pricing plans.

Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.

A new Supreme Court decision could throw into question $300 million in talc verdicts against Johnson & Johnson.

Mylan, which already has a low tax rate by being based in the Netherlands, has cut it into the single digits by investing in refined coal plants.

After scoring impressive numbers with its science-focused TV ad, Pfizer is preparing to launch another next month starring one of its own scientists.

Hands do the talking in new TV commercials for an Endo disease awareness campaign highlighting Dupuytren's contracture.